BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics
BridgeBio Pharma, Inc. (BBIO)
Today's Latest Price: $27.85 USD
Updated Aug 6 6:55pm
Add BBIO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
BBIO Stock Summary
- BridgeBio Pharma Inc's stock had its IPO on June 27, 2019, making it an older stock than just 0.5% of US equities in our set.
- With a price/sales ratio of 81.99, BridgeBio Pharma Inc has a higher such ratio than 96.87% of stocks in our set.
- With a year-over-year growth in debt of 761.32%, BridgeBio Pharma Inc's debt growth rate surpasses 97.6% of about US stocks.
- Stocks that are quantitatively similar to BBIO, based on their financial statements, market capitalization, and price volatility, are DCPH, ORMP, CYTK, FOLD, and BGNE.
- Visit BBIO's SEC page to see the company's official filings. To visit the company's web site, go to bridgebio.com.
BBIO Stock Price Chart Technical Analysis Charts
BBIO Price/Volume Stats
| Current price | $27.85 | 52-week high | $48.36 |
| Prev. close | $27.70 | 52-week low | $14.23 |
| Day low | $27.00 | Volume | 248,200 |
| Day high | $28.22 | Avg. volume | 770,561 |
| 50-day MA | $30.48 | Dividend yield | N/A |
| 200-day MA | $30.56 | Market Cap | 3.40B |
BridgeBio Pharma, Inc. (BBIO) Company Bio
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Loading social stream, please wait...